HCM
NASDAQ
$11.32
HUTCHMED (China) Ltd (HCM)
HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. The company is headquartered in Central, Hong Kong.
Sector:
Healthcare
Buy
Target: $22.62 (+99.82%)
Market Cap
$1.99B
PEG Ratio
0.00
Profit Margin
83.3%
P/E Ratio
4.35
Price Chart
Valuation
Market Cap$1.99B
P/E4.35
Forward P/E12.42
PEG0.00
P/S3.53
P/B1.56
Profitability
Total Revenue (TTM)$549M
Gross Profit (TTM)$64M
EBITDA-$26M
Profit Margin83.3%
Operating Margin-7.1%
EPS$2.66
Financial Health
Debt-to-Equity7.5%
Free Cash Flow Yield-3.96%
Growth & Risk
Revenue 5Y CAGR+19.20%
FCF 5Y CAGR+2.39%
Beta (5Y)0.81
Sharpe Ratio-1.07